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Alzheimer’s disease is characterized by the aberrant deposition of protein in the brain
and is the leading cause of dementia worldwide. Increasingly, there have been reports of
the presence of these protein hallmarks in the retina. In this study, we assayed the retina
of 5xFAD mice, a transgenic model of amyloid deposition known to exhibit dementia-like
symptoms with age. Using OCT, we found that the retinal nerve fiber layer was thinner in
5xFAD at 6, 12, and 17 months of age compared with wild-type littermates, but the inner
plexiform layer was thicker at 6 months old. Retinal function showed reduced ganglion
cell responses to light in 5xFAD at 6, 12, and 17 months of age. This functional loss was
observed in the outer retina at 17 months of age but not in younger mice. We showed
using immunohistochemistry and ELISA that soluble and insoluble amyloid was present
in the retina and brain at all ages. In conclusion, we report that amyloid is present in
brain and retina of 5xFAD mice and that the pattern of neuronal dysfunction occurs in
the inner retina at the early ages and progresses to encompass the outer retina with age.
This implies that the inner retina is more sensitive to amyloid changes in early disease
and that the outer retina is also affected with disease progression.
Keywords: retina, Alzheimer’s disease, electroretinography, optical coherence tomography, mouse
INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia worldwide. The disease is
characterized by abnormal processing and clearance of beta-amyloid (Aβ) and tau protein leading
to the formation of Aβ plaques and neurofibrillary tangles in the central nervous system (Hardy and
Higgins, 1992). These neurotoxic proteins have been shown to contribute to multiple pathological
processes involving neuronal inflammation as evidenced by microgliosis and astrocytosis, followed
by oxidative stress, mitochondrial dysfunction, impaired synaptic transmission, and neuronal
apoptosis (Musiek and Holtzman, 2015; Selkoe and Hardy, 2016). Clinically, a range of symptoms
most typically characterized by progressive memory loss and a decline in executive function (Wang
et al., 2017) is observed. A report by the World Health Organization estimates that the average
survival from disease onset is 4.6 years, with a median of 7.1 years (WHO, 2012). Whilst the disease
is formally diagnosed through a histopathological examination post-mortem, Aβ biomarkers such
as positron emission tomography and cerebrospinal fluid assays have been shown to detect the
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disease up to 20 years before clinical onset (Masters et al., 2015).
As these tests are either invasive or difficult to access outside of
research institutions, there has been a move toward developing
more accessible biomarkers.
Anatomically, the sensory retina and neurons of the cortex
have a common developmental origin and share many structural
and functional similarities (Wallace, 2011). This opens the
possibility of using the retina as a biomarker for cortical diseases
such as dementia (Guo et al., 2010; Lim et al., 2016; Nguyen
et al., 2017). Epidemiological surveys suggest that patients with
early stage dementia show changes in the neural retina, such as
thinning of retinal ganglion cell axons in the retinal nerve fiber
layer (Ascaso et al., 2014; Cheung et al., 2015; Ko et al., 2016).
This thinning and the associated inner retinal dysfunction (Katz
et al., 1989; Trick et al., 1989; Parisi et al., 2001) has been shown
to correlate with mini-mental state scores (Ko et al., 2016) in
those with AD. These studies highlight the possibility that AD
pathology might produce a specific pattern of retinal structural
and functional deficits. This has since lead to a rapid increase in
studies searching for viable ocular biomarkers of AD.
Although some studies have been able to detect Aβ in human
AD retinae (La Morgia et al., 2016; Koronyo et al., 2017; Grimaldi
et al., 2019), others have failed to confirm the presence of retinal
plaques (Schon et al., 2012; Ho et al., 2013; Williams et al.,
2017). In murine models of AD that overexpress Aβ in the brain,
studies have also found that Aβ is present in the retinae of a
variety of strains such as the Tg2576 (Dutescu et al., 2009; Liu
et al., 2009; Alexandrov et al., 2011), APP/PS1 (Ning et al., 2008;
Perez et al., 2009; Alexandrov et al., 2011; Gupta et al., 2016),
3xTg (Alexandrov et al., 2011; Grimaldi et al., 2018) TgCRND8
(Buccarello et al., 2017) TgF344 (Tsai et al., 2014), and 5xFAD
(Alexandrov et al., 2011). In APP/PS1 (Ning et al., 2008; Gupta
et al., 2016) and Tg2576 (Dutescu et al., 2009; Liu et al., 2009)
mice, Aβ deposits were found in the inner retina near the output
cells of the eye, the ganglion cells and their dendrites and axons.
Quantitative comparisons in 3xTg mice indicate similar findings
of early inner retinal Aβ-plaque deposition followed by later outer
retinal deposits (Grimaldi et al., 2018). Whether mouse models
of retinal Aβ also exhibit both in vivo structural and functional
correlates remains incompletely investigated.
Human studies indicate a predilection of retinal ganglion cell
related losses in AD patients. This is supported by deposition
of Aβ in inner retinal layers (La Morgia et al., 2016; Koronyo
et al., 2017) as well as losses in pattern electroretinography and
retinal nerve fiber layer (RNFL) thinning with optical coherence
tomography (OCT), reviewed elsewhere (Thomson et al., 2015;
Lim et al., 2016; den Haan et al., 2017; Nguyen et al., 2017;
Chan et al., 2019). Ganglion cell inner plexiform layer (GCIPL)
thinning has also been reported (Chan et al., 2019), however,
early in the disease thickening may also occur in this layer
(Snyder et al., 2016). In contrast, electroretinography (ERG)
assessment in mouse models of Aβ deposition at times show
conflicting results. Some studies indicate for an improvement in
ERG with APP/PS1 (Joly et al., 2017) and 3xTg mice (Chiquita
et al., 2019) whereas others indicate for retinal dysfunction in
APP/PS1 (Perez et al., 2009; Gupta et al., 2016; Georgevsky et al.,
2019). It is possible in the APP/PS1 mice that this may reflect a
difference in ages and ERG parameters assessed, however, some
controversy still remains. OCT changes in transgenic mouse
models indicate for consistent inner retinal thinning, however,
this is preferential [TgCRND8 mice (Buccarello et al., 2017)]
or in parallel to outer retinal changes [APP/PS1 (Georgevsky
et al., 2019), 3xTg mice (Chiquita et al., 2019)]. Importantly
only two studies have investigated both ERG and OCT in a
murine model (Chiquita et al., 2019; Georgevsky et al., 2019).
What is currently lacking is an understanding of the time
course of structural changes and their corresponding function,
particularly in the inner retinal layers, which is more commonly
reported in humans.
The work of Criscuolo et al. (2018) indicates the 5xFAD model
may be a useful one to study vision changes which recapitulate
human AD as functional measures indicate that retinal ganglion
cell derived pattern ERG declines faster than middle/outer retinal
full field ERG responses. We extend this work in 5xFAD mice by
studying whether inner retinal functional changes in these mice
are mirrored by structural changes with increasing age. These
mice have undergone quantitative immunohistochemical (IHC)
analyses and indicate for the presence of both Aβ oligomers and
Aβ plaques in the retinae and brains (Habiba et al., 2020). The
current study extends this by using ELISA with qualitative IHC
to examine the age-related pattern of soluble and insoluble Aβ
and how this reflects on retinal structure and function in the
5xFAD mouse model.
MATERIALS AND METHODS
General Procedures
All procedures were conducted in accordance with the National
Health and Medical Research Council Australian Code of
Practice for the care and use of animals for scientific
purposes. Ethics approval was obtained from the Howard
Florey Institute Animal Experimentation Ethics Committee
(Approval number 13-068-UM). Mice used in this study B6.CgTg
(APPSwFlLon,PSEN1∗M146L∗L286V) 6799Vas/Mmjax, carry
three human APP mutations and two PSEN mutations, hence
termed “5xFAD.” In this model, amyloid expression is driven by
a neuron-specific Thy1 promoter, allowing for the accumulation
of high levels of Aβ42 in the cortex, rapidly recapitulating the
features of AD which include amyloid plaque formation in the
cortex and behavioral changes such as memory impairment
(Oakley et al., 2006). The strain used in this study (MMRRC Stock
34848, Jackson Laboratories, Bar Harbor, ME, United States) are
segregating hemizygous/wildtype for the disease and are bred
on a C57BL/6J background and backcrossed such that they do
not carry the retinal degeneration allele Pde6brd1. Due to the
congenic background of these mice, non-transgenic littermates
(WT) were used as a control (Oakley et al., 2006).
Mice were examined at three ages, namely 6, 12, and 17
months of age. A total of 32 5xFAD and 38 WT mice were
used. Each age group underwent non-invasive assessment of
retinal structure and function on separate occasions. Before
each procedure, animals were weighed and anesthetized with an
intraperitoneal injection of ketamine (80 mg/kg) and xylazine
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(10 mg/kg). The mixture was diluted in sterile injectable saline
(1:10) to aid with hydration and ease of administration (10 µl/g).
Topical anesthesia and pupil mydriasis were achieved with
drops of proxymetacaine 0.5% and tropicamide 0.5% (AlcaineTM
and MydriacylTM, respectively, Alcon Laboratories, Frenchs
Forest, NSW, Australia). Corneal hydration was maintained
with either lubricating eye drops or eye gel (Systane R© or
Genteal R©, Novartis Pharmaceuticals Australia). At the end
of the final experiment, anesthetized animals were culled
by cervical dislocation. Eye and brain tissues were collected
postmortem for assessment.
Electroretinography
Mice were dark adapted overnight prior to ERG recording
(5xFAD, n = 11–15/age; WT, n = 8–12/age). As previously
described (Nguyen et al., 2016; Zhao et al., 2017), experiments
were conducted in a lightproof room with the aid of a dim red
light in order to preserve dark adaptation. Upon induction of
anesthesia and mydriasis, animals were lightly secured to a heated
platform with straps to minimize movement and breathing
artifacts. A custom made chlorided silver active electrode (A&E
Metal Merchants, NSW, Australia) was placed upon the central
cornea, with the inactive placed around the sclera and the
reference electrode (Grass Telefactor, RI, United States) inserted
subcutaneously into the tail, before positioning the Ganzfeld
bowl at eye level. ERGs were elicited using a range of increasing
luminous energies. This range of stimuli allows for the isolation
of ganglion cell (scotopic threshold response, STR), inner retinal
inhibitory circuits (oscillatory potentials, OPs), bipolar cell (P2),
and photoreceptor (P3) response amplitudes and timings. ERG
parameters returned from the analysis include the P3 (RmP3), P2
(Vmax), OP, and pSTR amplitudes, the P3 and P2 sensitivities, in
addition to the OP and pSTR implicit times.
Analysis of the ERG has been described in detail previously
(Nguyen et al., 2016; Zhao et al., 2017). In brief, the first
electronegative component of the ERG waveform was modeled
using a delayed gaussian function to expose the P3. This is
subtracted from the waveform to isolate the P2-OP complex. The
OPs are separated from the P2 by transforming the data into
the frequency domain via discrete fourier transform, followed by
the filtering using a digital band pass filter (50–180 Hz, −3 dB).
The STR parameters are averaged over three luminous energies,
−4.90, −5.01, and −5.31 log cd·s/m2 in order to assess retinal
ganglion cell function.
Optical Coherence Tomography
Retinal structure was measured (5xFAD, n = 8–14/age; WT,
n = 8–16/age) using spectral domain-OCT (Envisu-R2200, Leica
Microsystems, Buffalo Grove, IL, United States). Retinal volumes
(1.4 × 1.4 × 1.57 mm) centered at the optic nerve head were
acquired using 200 evenly distributed horizontal B-scans, each
made up of 1000 A-scans. This yielded a volume with a lateral
resolution of 7 µm superiorly to inferiorly, with an axial depth
resolution of 2.8 µm. For analysis, images were extracted as a
TIFF stack and quantified using FIJI software (National Institutes
of Health, Bethesda, MD, United States). Retinal layers in the
central b-scan were manually segmented in a masked fashion
into the retinal nerve fiber layer (RNFL), ganglion cell complex
(GCC), and total retinal thickness (TRT) components. The
difference between GCC and RNFL was taken to be the inner
plexiform layer (IPL), whilst the difference between TRT and
GCC was taken to be the outer retinal layer (ORT).
Immunohistochemistry
Mice were perfused with heparinized phosphate buffered saline.
Whole eye and brain tissues were dissected and fixed in
10% neutral buffered formalin overnight and embedded in
paraffin for sectioning. Sagittal sections 7 µm in thickness
were cut and treated with 80% formic acid and 3% hydrogen
peroxide prior to incubation in blocking buffer (50 mM
Tris-HCl, 175 mM NaCl, pH 7.4, with 20% blocking serum
corresponding to species for secondary Aβ). In the brain a
total of 135 sections were obtained while 1272 retinal sections
were obtained from 6 5xFAD mice and 3 WT. Monoclonal
antibodies 1E8 and WO2 were obtained in-house and have
been previously validated (Ida et al., 1996; Allsop et al., 1997;
Li et al., 1998; Tammer et al., 2002; George et al., 2006).
They were used at dilutions of 1:500 and 1:1000, respectively.
Sections were washed and incubated with biotinylated secondary
antibody and streptavidin/horseradish peroxidase reagent (Dako
LSAB R© + HRP kit, Agilent Technologies Australia, Mulgrave
VIC, Australia), followed by chromogen for color development
(Dako DAB + chromogen kit, Agilent Technologies Australia,
Mulgrave VIC, Australia). Slides were counterstained in Harris’s
Haematoxylin (Australian Biostain, Traralgon, VIC, Australia),
before mounting in distyrene-plasticizer-xylene media (DPX
new, Merck Millipore, Bayswater, VIC, Australia). Before each
run, a sample whereby the primary antibody was removed
served as a negative control. IHC staining of frontal cortex and
hippocampus were quantified as described by Wilcock et al.
(2006) In brief, amyloid deposits were first thresholded in a
masked fashion according to a fixed hue-saturation-intensity
used across all images of the same magnification. In order to
incorporate both size and number of Aβ plaques in a given image,
the stain area is quantified as a percentage of the total area of the
given image. Three sections at each location from each mouse
(6 months 5xFAD n = 3, WT n = 1; 12 months 5xFAD n = 3,
WT n = 1, 17 months 5xFAD n = 3, WT n = 1) was assessed and
averaged into a single parameter for each individual animal.
Protein Assay
Eye and brain tissues were snap frozen in liquid nitrogen
immediately after collection. Eyes were dissected with the aid of
a microscope in order to retrieve the retinae. In short, an eye cup
was created by cutting circumferentially around the limbus. The
lens and vitreous were removed with tweezers and four relaxing
incisions were made to the globe to yield a flat mount. The retinal
tissue was then isolated by gently leveraging it from the sclera
with a Tooke knife (AS4-020, Aurora Surgical LLC, St Petersburg,
FL, United States). Due to the small volume of retinal tissue,
which is estimated to be ∼10 mg when wet (Okawa et al., 2008),
and in accordance with pilot studies 6–8 retinae of the same age
group and genotype were pooled into one sample for protein
assays. Brains were assayed individually.
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Each sample was homogenized in either 1000 µl (brain) or
200 µl (retina) of saline buffer containing a protease/phosphotase
inhibitor (HaltTM Protease and Phosphatase Inhibitor Cocktail
100X, ThermoFischer, Scoresby, VIC, Australia) using a
sonicator (Branson digital sonifier, Model S450, Danbury, CT,
United States) with 30 second bursts on ice until tissues were
visibly homogenized. As previously described (McLean et al.,
1999; Adlard et al., 2014; Roberts et al., 2017), the homogenate
was then separated using an ultracentrifuge (OptimaTM Max-E,
Beckman Coulter Australia, Lane Cove, NSW, Australia) at
100,000× g on a 1-h spin cycle at 4◦C. The resulting supernatant
was analyzed for “soluble” protein. The pellet was re-suspended
in protease inhibitor buffered saline and homogenized again
to create the “insoluble” protein sample. Samples were then
aliquoted for protein analysis described below.
Total Protein Quantification Using Bicinchoninic Acid
Assay
Total protein levels of the soluble and insoluble samples
were determined with bicinchoninic acid (BCA) assay (Pierce
Biotechnology, Rockford, IL, United States). Aliquots (5 µl) of
soluble eye and brain samples were diluted in dH2O at a ratio
of 1:10 and 1:20. Insoluble eye and brain aliquots (200, 1000
µl, respectively) were diluted at ratios of 1:20 and 1:40. Once
diluted, 10 µl samples were added into well plates containing
200 µl of BCA working buffer and incubated at 37◦C for
30 min. Once developed, the samples, along with known standard
albumin concentrations were evaluated on a plate reader (Wallac
1420 Victor2 microplate reader, Perkin Elmer, Waltham, MA,
United States) using a 560 nm source. Standard concentrations
values were used to derive a standard curve in order to determine
the final total protein concentration of the samples. Samples were
run in duplicate to reduce variability.
Amyloid Protein Quantification Using ELISA
Enzyme-linked immunosorbent assay was performed for
quantification of total Aβ using W02 primary antibody-coated
well plates. After washing, the samples were blocked with
0.5% casein/PBS and washed, prior to the addition of 10 µl of
detection antibody, 1E8-Biotin (2 ng/µl) into each well. Aβ40
standards (50 µl) with known concentration were made up
using serial dilution in order to establish the standard curve.
Soluble (50 µl) samples were directly loaded into each well.
Insoluble 5 µl aliquots were first diluted in 15 µl formic acid
(1:4) and left to solubilize for 1 h, followed the addition of 1 M
Tris (1:20) and PBS/casein (1:5); before being loaded into each
well at 50 µl volumes. Samples were then incubated overnight at
4◦C. After washing, Streptavidin-Europium (Delfia R© 1244-360,
Perkin Elmer, Boston, MA, United States) in 1:1000 PBST/casein
was added and the solution was incubated for 1 h at room
temperature. After washing, enhancement solution (Delfia R©
1244-105 Perkin Elmer, Boston, MA, United States) was added
to each well before being loaded into the plate reader. Plates were
read using excitation at 340 nm and emission at 650 nm in order
to determine Aβ concentration. 5xFAD and wild type tissue
were assayed and the reliable detection limit was determined
by loading tissue from the soluble and insoluble fraction of the
controls. The transgenic retinal tissue was above this limit and
illustrated in Figure 3. Results are expressed as Aβ (pg) per mg of
total protein as determined using BCA. To facilitate comparison
between retina and brain samples Aβ levels are normalized to
protein concentration (in mg).
Data Analysis and Statistics
Statistical comparisons were carried out using two-way ANOVA
to establish differences between treatment and time effects.
Two-way ANOVA post hoc tests with Bonferroni correction for
multiple comparisons were used to compare between groups.
Normality was established using a Kolmogorov-Smirnov test.
An alpha of 0.05 was considered to be statistically significant.
Statistical analyses were carried out in Prism 6 (GraphPad, La
Jolla, CA, United States).
Results
Immunohistochemistry
Amyloid Deposits in the Brain Increases With Age
Brain sections of 5xFAD and wildtype (WT) mice at 6, 12,
and 17 months of age underwent immunohistochemical (IHC)
staining using Aβ specific 1E8 antibodies (Dutescu et al.,
2009; Figure 1). Background structures were outlined using
haematoxylin stains. Figures 1A–H show representative images
where Aβ immunoreactivity increases with age (brown staining).
This is further quantified for the percent area of Aβ staining
(Figure 1I) and illustrates an increase in the 5xFAD sections
(R2 = 0.72, p< 0.001) but not age-matched controls.
Discrete Amyloid Deposits Were Rare but Detectable
in the Retinae of 5xFAD
The same 1E8 antibody and IHC staining protocol was used in
the retina. A total of nine animals, aged 6, 12, and 17 months
were examined (two 5xFAD and one WT animal per age group,
Figure 2). Of the six 5xFAD animals, only four animals aged 6
(n = 1), 12 (n = 1), and 17 months (n = 2) showed Aβ reactivity in
the retina. None of the WT mice examined (165 sections across 3
WT retinae) were positive for Aβ.
Detection of Aβ staining in retinal serial sections (7 µm)
of 5xFAD mice proved elusive, with only 16 out of the 1,107
sections (1.4%) examined showing positive Aβ staining. There
appears to be a preference for the staining (50%, 8 of 16
sections) to occur in the ganglion cell layer (GCL) and inner
plexiform layer (IPL, Figure 2). The remaining 50% of the
staining was found in the inner nuclear layer (INL, n = 1),
outer plexiform layer (OPL, n = 1) and outer nuclear layer
(ONL, n = 6). In 6-month-old 5xFAD, retinal staining was
limited to the inner retinal layer, with no immunoreactivity in
the outer retina.
Amyloid Protein Assay
Amyloid Quantification Using ELISA Shows Increased
Protein Expression With Age
Soluble Aβ in the brain and retina showed similar levels
[Figure 3A, two-way ANOVA F(1, 41) = 0.55, p = 0.46]. In
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FIGURE 1 | Expression of Aβ in 5xFAD mouse brain at 6, 12, and 17 months of age. Aβ labeling using monoclonal mouse antibody 1E8 (brown) and counterstained
with haematoxylin (blue). Representative cortical and hippocampal parasagittal serial sections of 12-month-old wild type (A,E); and 5xFAD mice at ages 6 (B,F), 12
(C,G), and 17 (D,H) months of age. There is a significant increase in Aβ area stained with advancing age in 5xFAD mice (I) Scale bar, 400 µm.
FIGURE 2 | Aβ was detectable in 5xFAD mice retinae at various ages. 1E8
labeled serial sections counterstained with haematoxylin showed Aβ
immunoreactivity in the inner and outer retina of 5xFAD mice. 1E8 staining
absent in (A) a 6-month-old WT mouse retina and (B) a negative control in a
6-month-old 5xFAD retina. 1E8 staining present in (C) a 6-month-old 5xFAD
retina (D) a 12-month-old 5xFAD retina and (E,F) a 17-month-old 5xFAD
retina. Positive Aβ staining was seen in the ganglion cell layer, inner plexiform
layer, the inner and outer nuclear layers as marked by red arrows. Images
feature tangential cuts to the retina which preclude meaningful thickness
comparison. Scale bars, 50 µm; GCL, ganglion cell layer; IPL, inner plexiform
layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear
layer; OS, outer segments. Disclosure: separate histological sections from a
subset of these animals have been displayed in another manuscript (Hadoux
et al., 2019).
contrast, Figure 3B illustrates the difference in insoluble Aβ
between the retina and the brain at each age. Here, we found
that insoluble retinal Aβ was significantly lower than brain levels
[two-way ANOVA, tissue effect, F(1, 41) = 22.47, p< 0.01] which
may account for the relative sparsity of amyloid deposits in
retinal sections examined with IHC (Figure 2). Post hoc analysis
(Bonferroni test, 6 vs. 17 months, p < 0.05) indicates for a
reduction in insoluble Aβ in the brain with advancing age. This is
counter to our a priori expectation as IHC showed an age-related
increase in Aβ density in the cortex of these mice (Figure 1).
In vivo Retinal Structure in 5xFAD Mice
Optical Coherence Tomography Reveals Selective
Inner Retinal Thinning in 5xFAD
Optical coherence tomography (OCT) allows for the in vivo
assessment of specific retinal layer thicknesses, avoiding potential
confounds associated with tissue preparation and fixation
(Ferguson et al., 2014). Both 5xFAD and WT controls were
assayed at 6 (5xFAD n = 8, WT n = 13), 12 (5xFAD n = 12,
WT n = 13) and 17 months of age (5xFAD n = 14, WT
n = 16). Figure 4 shows representative OCT images, raw layer
thickness values, and layer thickness expressed relative to 6-
month-old WT littermates.
The RNFL layer was significantly thinner in 5xFAD mice
compared with WT animals [Figures 4C,H, two-way ANOVA,
genotype effect, F(2, 70) = 38.90, p < 0.01]. There were
no significant interactions or age effects. Bonferroni post hoc
analysis showed that the RNFL thinning in 5xFAD mice
was significant at all ages assessed (6 months, p < 0.01;
12 months, p < 0.05; 17 months, p < 0.01). Similarly,
ganglion cell complex (GCC) thickness, which includes RNFL,
ganglion cell bodies and their synaptic layer (the inner
plexiform layer, IPL), was reduced in 5xFAD compared with
WT [Figures 4E,J, two-way ANOVA, genotype effect, F(1,
70) = 7.64, p = 0.01]. No significant interaction or age
effect was found.
When compared between genotypes, the IPL in 5xFAD mice
was significantly thicker than WT mice [Figures 4D,I, two-
way ANOVA, genotype effect, F(1, 70) = 11.43, p < 0.01].
This was especially so in the 6-month-old group (Bonferroni,
6 months, p < 0.01). Thus, the amount of RNFL thinning
outweighed that of IPL thickening, which manifest as an overall
thinning of the GCC.
Outer retinal thickness (ORT) was defined by the difference
between the total thickness of the retina minus the inner
retinal layers (GCC). This area represents a combination of
layers where the cell bodies of photoreceptors, horizontal
cells, bipolar cells and amacrine cells and their synaptic
layers exist. There was a slight but significant age-related
increase in ORT [two-way ANOVA, age effect, F(1, 70) = 7.64,
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FIGURE 3 | Aβ levels in 5xFAD brain and retina using ELISA. (A) Soluble Aβ in the brain increased with age but remained unchanged in the retina with age. Soluble
Aβ levels in the retina were comparable to that of the brain. (B) Insoluble Aβ levels in the retina were lower than that of the brain. Aβ was not detected in WT mice
(not shown). Bars, Mean ± SEM; #p < 0.05 for tissue effect on two-way ANOVA analyses. *p < 0.05 for Bonferroni post hoc tests.
p < 0.01]. However, there was no significant interaction or
genotype differences.
Total retinal thickness (TRT) provides a measure of age and
phenotype effects on the retinal as a whole and allows for the
comparison of the relative magnitude of change between the
inner and outer retinal layer. In this instance, both genotypes
showed a small increase in TRT with age [two-way ANOVA, age
effect, F(1, 70) = 6.75, p< 0.01], with no significant interaction or
genotype differences.
Retinal Function in 5xFAD Mice
Group averaged electroretinogram (ERG) waveforms (age 6, 12,
17 months: 5xFAD n = 8, 12, 12, respectively; WT n = 11, 12, 15,
respectively) are shown in Figure 5. The ganglion cell dominated
scotopic threshold response (STR) elicited with the dimmest
flashes is shown in the lowest traces. Rod dominant responses
are elicited for luminous energies up to ˜−0.8 log cd·s/m2.
For brighter stimuli, the ERG is a mixed signal containing
contributions from both rod and cone pathways. In WT mice,
waveforms were attenuated with advancing age. This attenuation
appeared to be consistent for all ERG components.
When comparing 5xFAD and WT, attenuation of the STR
response (Figure 5A, bottom panels −5.01—4.87 log cd·s/m2)
was seen at 6 months of age in 5xFAD mice. At this age,
ERG responses arising from the outer retina appeared relatively
normal. This pattern of functional deficits was also observed in
12-month-old 5xFAD mice (Figure 5B). However, by 17 months
of age reduced inner retinal function in 5xFAD mice is also
accompanied by outer retinal dysfunction as evident in deficits
in responses elicited with medium to higher stimulus energies
(Figure 5C,−0.81–2.07 log cd·s/m2).
These observations are confirmed in analysis of the ERG
components (Figure 6). Photoreceptoral amplitudes declined
with age and were smaller in 5xFAD mice [Figures 6A,I, P3, two-
way ANOVA, age effect, F(2, 64) = 10.82, p < 0.01; genotype
effect, F(2, 64) = 7.26, p = 0.01]. Bonferroni post hoc analysis
revealed a difference between 5xFAD and WT at 17 months of age
(p < 0.05), but not at 6 or 12 months of age (6 months, p > 0.99;
12 months, p = 0.65).
Photoreceptoral sensitivity showed an age-related difference
[two-way ANOVA, age effect, F(2, 64) = 5.12, p < 0.01] but
no genotype change [two-way ANOVA, genotype effect, F(2,
64) = 3.59, p = 0.06]. None of the photoreceptoral parameters
showed interaction effects.
Bipolar cell responses were significantly attenuated with age,
with 5xFAD mice showing significant dysfunction [Figures 6B,J,
P2, two-way ANOVA, age effect, F(2, 64) = 14.09, p < 0.01;
genotype effect, F(2, 64) = 6.08, p < 0.05]. Post hoc analysis
highlighted a difference between 5xFAD and WT at 17 months,
with no difference at 6 or 12 months of age (Bonferroni, 6 months,
p > 0.99; 12 months, p > 0.99; 17 months, p < 0.05). Bipolar cell
sensitivity showed a significant change with age [Figures 6F,N,K,
two-way ANOVA, age effect, F(2, 64) = 4.98, p < 0.01] but no
difference between genotypes [K, two-way ANOVA, genotype
effect, F(2, 64) = 4.98, p = 0.06]. There were no interaction effects
in bipolar cell parameters.
Inner retinal inhibitory circuits involving amacrine cell
function, as indicated by the amplitude of the OPs, was attenuated
with age and in 5xFAD mice [Figures 6C,K, OP, two-way
ANOVA, age effect, F(2, 64) = 8.21, p < 0.01; genotype effect,
F(2, 64) = 7.06, p < 0.01]. Post hoc analysis showed no difference
at ages 6 and 12 months but significantly smaller OPs in 5xFAD
mice at 17 months of age (Bonferroni, 6 months, p > 0.99;
12 months, p = 0.33; 17 months, p < 0.01). OP implicit
time was delayed with age [Figures 6G,O, two-way ANOVA,
age effect, F(2, 64) = 5.93, p < 0.01; genotype effect, F(2,
64) = 4.38, p = 0.04], and was generally slower in 5xFAD
mice. Similarly, ganglion cell function declined with age and
was smaller in 5xFAD compared with WT mice [Figures 6D,L,
pSTR, two-way ANOVA, F(2, 64) = 17.90, p < 0.01 and F(2,
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FIGURE 4 | Age-related structural changes in 5xFAD examined using optical coherence tomography. Mouse retinas were assayed for structural changes at 6 (5xFAD
n = 8, WT n = 13), 12 (5xFAD n = 12, WT n = 13) and 17 months (5xFAD n = 14, WT n = 16) of age and genotype differences were compared. (A,B) Representative
WT and 5xFAD OCT images, respectively. (C–G) Raw retinal thickness values. (H–L) Retinal thickness values expressed as a percentage of 6-month-old WT. RNFL
and GCC thickness were significantly reduced and IPL was significantly increased in 5xFAD mice. No significant changes were found in ORT or TRT. Scale bar,
50µm; RNFL, retinal nerve fiber layer; IPL, inner plexiform layer; GCC, ganglion cell complex; ORT, outer retinal thickness; TRT, total retinal thickness; Error bars,
SEM; Gray shaded area, 95% CI for 6-month-old WT; #p < 0.05 for treatment effect on two-way ANOVA analyses; *p < 0.05 for Bonferroni post hoc tests.
64) = 26.51, p < 0.01, respectively]. In contrast to the other ERG
parameters, the pSTR in 5xFAD mice was significantly reduced
at 6 months of age. This difference persisted across all ages
(Bonferroni, 6 months, p< 0.05; 12 months, p< 0.01; 17 months,
p = 0.02). No difference in the implicit time of the pSTR was
noted (Figure 6H).
In order to better visualize the relative change between
inner and outer ERG parameters, data were normalized to
the 6-month-old WT group and expressed as a percentage
(Figures 6I–P). In WT mice, age-related decline in outer retinal
responses (P3 and P2) was seen at 12 months. However,
significant inner retinal decline (OPs and pSTR) was only evident
at 17 months of age. In 5xFAD mice, ganglion cell dysfunction
was evident at 6 months of age. Between 6 and 12 months of age
outer retinal function in 5xFAD mice appeared to decline at a
similar rate to WT mice. Between 12 and 17 months of age, outer
retinal function (P3 and P2) along with the OPs in 5xFAD mice
appeared to decline faster compared with WT mice.
DISCUSSION
Our study shows ERG and OCT changes that indicate for
a preferential effect on the inner retina in 5xFAD mice.
More specifically, we show that 6-month-old mice exhibited
preferential inner RNFL thinning (Figures 4C,H) in the absence
of outer retinal changes (Figures 4F,G,K,L) using OCT. This
finding was, similarly, reported in 3-month-old TgCRND AD
mice (Buccarello et al., 2017). To our knowledge, only two other
studies have performed a time course of OCT assessment in AD
mouse models, though direct comparison is limited due to the
different segmentation methods used. Nevertheless, in 3xTg AD
mice, Chiquita et al. (2019) reported inner retinal (GCL+IPL)
thinning at the earliest time-point (4 months) before significant
changes to middle and outer retinal layers (INL+OPL, ONL, and
IS+OS layers) at 8, 12, and 16 months old). In APP/PS1 mice,
Georgevsky et al. (2019) also examined a time-course (3, 6, 9,
and 12 months old) of OCT changes and reported both inner
retinal (ILM to INL) and outer retinal changes (OPL to RPE),
with a trend toward greater sensitivity occurring in the inner
retina. As such the early preferential inner retinal thinning is
consistent across studies.
Similarly, clinical human AD studies commonly report RNFL
thinning across all stages of the disease (Thomson et al., 2015;
den Haan et al., 2017; Chan et al., 2019). The IPL, however,
has received less attention. Snyder et al. (2016) found that in
those who were at risk of AD (e.g., PET biomarker positive),
there was a selective trend toward greater IPL volumes which
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FIGURE 5 | Age-related changes in retinal function in 5xFAD mice. Grouped averaged waveforms are shown for (A) 6-month-old (B) 12-month-old (C)
17-month-old mice. Lower panels show the ganglion cell dominated STR response (−5.01 to −4.87 log cd·s/m2). Rod and mixed rod-cone response are elicited
with increasing luminous energies. The uppermost panel reflects the cone response isolated using a twin-flash paradigm. STR, scotopic threshold response –
ganglion cell dominant; pSTR, positive STR; nSTR, negative STR; a-wave – photoreceptoral response; b-wave – bipolar cell response; oscillatory potentials –
amacrine cell dominant.
significantly correlated with surface area of retinal inclusion
bodies (suggested to contain Aβ). Similarly, Ascaso et al. (2014)
found a thickening of total macula thickness with concurrent
RNFL thinning in MCI patients, whereas thinning of both
RNFL and macular thickness was observed in those with AD.
Consistent with this, we report initial IPL thickening at 6 months
(Figures 4D,I) but not at older ages. Whether this is due
to amyloid deposition or gliosis resulting from inflammation
(Ning et al., 2008; Perez et al., 2009) in 5xFAD mice requires
further evaluation.
Functionally, 5xFAD mice show attenuation of the ganglion
cell dominated pSTR, with no changes to bipolar, amacrine and
photoreceptor mediated responses at 6 months (Figures 5, 6),
consistent with the observed structural change in the inner retina
and inner retinal amyloid deposits. In comparison with the
literature, our findings were most consistent with other studies
employing retinal ganglion cell measures in APP/PS1 (Gupta
et al., 2016) and 5xFAD (Criscuolo et al., 2018). These ERG
deficits corroborate previous reports of ganglion cell dysfunction
in clinical cohorts with AD (Katz et al., 1989; Trick et al.,
1989; Parisi et al., 2001; Krasodomska et al., 2010; Sartucci
et al., 2010). With advancing age, we show more generalized
dysfunction in 5xFAD mice, with significant reductions in P3
(photoreceptoral), P2 (bipolar cell), and OP amplitude (amacrine
cell) observed by 17 months of age (Figure 6). This is in
agreement with Perez et al. (2009) who found reductions in
a-wave (photoreceptor) and b-wave (bipolar cell) amplitudes in
12–16 month old APP/PS1 mice. Although this did not manifest
as an overall outer retinal thinning on OCT, dysfunction in cells
are known to precede structural changes (Fortune et al., 2012;
Fry et al., 2018; Georgevsky et al., 2019). Why other studies in
3xTg mice (Chiquita et al., 2019) and APP/PS1 mice (Joly et al.,
2017) show larger outer (a-wave) and middle retinal (b-wave)
responses in the rod and cone system could be explained by the
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FIGURE 6 | Age-related change in 5xFAD and WT ERG parameters. (A–D) Raw P3, P2, OP, and pSTR, respectively. (E,F) P3 and P2 sensitivity (units, log
cd-1.s-1.m2), respectively. (G,H) OP and pSTR implicit time (ms), respectively. (I–P) All ERG parameters normalized to 6-month-old WT to facilitate easier
comparison between parameters. The earliest functional change to occur in 5xFAD occurred in the pSTR. An overall trend toward ERG decline with age occurred in
all parameters. At 17 months of age, 5xFAD mice showed a significant decline in all ERG parameters. P3, photoreceptoral response; P2, bipolar cell response; OP,
oscillatory potentials; pSTR, positive scotopic threshold response; all data shown, mean ± SEM; #p < 0.05 for treatment effect on two-way ANOVA analyses;
*p < 0.05 for Bonferroni post hoc tests.
difference in their functional assessment or the animal model
used. This area requires further investigation. Taken together,
our ERG and OCT findings suggest that in 5xFAD mice there
is selective inner retina deficits at younger ages (6 months)
which progress to more widespread functional deficits at older
ages (17 months).
A recent study by our group has quantified
immunohistochemical staining of Aβ in retina and brains
in 5xFAD mice (Habiba et al., 2020). Some of the animals
used in the current study also underwent tissue assessment
in Habiba et al. (2020). Habiba et al. (2020) found that Aβ
plaque deposition increased with advancing age in the retina,
cortex and hippocampus of 5xFAD mice (6, 12 and > 14
months old). In contrast, Aβ oligomers were highest at 6
months and decreased with advancing age (12 and > 14
months old) in 5xFAD tissue. The inverse correlation between
Aβ-oligomers and Aβ-plaques was consistent with an age-
related conversion between the two. Analyses of age-matched
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wild-type controls showed higher levels in 5xFAD tissue.
These patterns are largely in agreement with the soluble and
insoluble ELISA conducted in the current study, however, due
to the necessity to pool tissue, ELISA was less sensitive to pick
up aging effects.
Alexandrov et al. (2011) compared Tg2576, 3xTg-AD, 5xFAD,
and PS/APP mouse models using ELISA and found retinal Aβ
in all models and highest in 5xFAD, most closely approximating
that found in human retina. Extending Alexandrov et al.
(2011) findings to multiple ages we found that retinal levels
of the more toxic soluble form of Aβ, particularly at 6 and
12 months of age, were comparable to that of the brain
(Figure 3A). In contrast, Habiba et al. (2020) found higher
levels of β oligomers in the cortical and hippocampal tissue
than retinal tissue which may reflect the higher specificity
to Aβ oligomers of the A11 antibody than the soluble
fraction of ELISA, which in addition to Aβ-oligomers also
includes Aβ-monomers and dimers. Figure 3B illustrates that
insoluble Aβ levels were much lower in the retina (˜5–
9 times lower) compared with the brain. This may explain
the relative ease with which amyloid plaques were detectable
using IHC staining in brain sections (Figure 1) compared
with their rarity in retina (Figure 2), a finding supported
by Habiba et al. (2020) and other studies using 5xFAD
mice and other animal models of AD (Dutescu et al., 2009;
Alexandrov et al., 2011).
Quantification of IHC in the brain shows increasing
deposition of Aβ plaques with advancing age (Figure 1I) in
accordance with Habiba et al. (2020) which conducted IHC
using additional stains (Congo red, Thioflavin-T, 4G8). This is
contrary to the findings of ELISA. One possibility was incomplete
solubilization of the amyloid aggregates in the samples using
formic acid treatment, which was performed over 1 hour. This
could lead to epitope masking and steric hindrance, resulting
in less antibody capture during ELISA (Janssen et al., 2015).
This is likely to be more pronounced with older 5xFAD tissue
given the likelihood of increasing plaque density (Figure 1)
and hardness of the plaques (Janssen et al., 2015). This may
have been less of an issue with retinal tissue, which has less
Aβ deposition.
In terms of anatomical localization, the IHC staining in
the current study (1E8) and that of Habiba et al. (2020)
(Congo red, Thioflavin-T 4G8 A11) suggests some inner
retinal preference that may extend to the outer retina
with advancing age. Although the distribution of Aβ in
the retina was only a qualitative observation, this is in
line with the literature. Grimaldi et al. (2018) found that
Aβ plaque (anti-Aβ D54D2) volume was significantly
elevated in 3xTg mice particularly evident in the inner
retina, increasing exponentially with age and spreading
to the outer retina. Similarly, Ning et al. (2008) found
an age-dependent deposition of Aβ in the RNFL layer
of APP/PS1 mice. In Tg2576 mice, two studies found
positive staining for Aβ using 1E8 (Dutescu et al., 2009)
and 6E10, 12F4, 5C3 (Liu et al., 2009) antibodies in the
inner retinal layers (Dutescu et al., 2009; Liu et al., 2009)
and some in the outer retinal layers (Liu et al., 2009). As
such in combination with our ERG and OCT changes,
collectively this lends some credence to the idea that retinal
amyloid pathology preferentially affects the inner retina,
in particular the retinal ganglion cells (Blanks et al., 1989;
Blanks et al., 1996).
This study has a number of limitations that are noteworthy.
Although serial sections were used to detect retinal Aβ,
with an interest in the retinal layer where such deposits
may reside, this may have led to an underestimation of the
frequency of Aβ staining. Due to the sparseness of retinal
Aβ staining, perhaps the use of retinal wholemounts and
confocal imaging (Park et al., 2014) would allow us to detect
more Aβ accumulations in the inner retinal layer. Whilst
we have shown inner retinal function loss corresponding
to RNFL thinning, the individual retinal layers were not
segmented or stained to show increased immunological
reactivity. Studies staining for glial activation and apoptosis
would be useful in the future, but is beyond the scope of
the current study.
Finally, the current study found deficits in retinal function
and structure even at the earliest time-point assessed (6
months of age) which corresponds to a relatively early
stage of pathogenesis in this animal model. Further studies
are required to examine even earlier time-points, before
cortical and behavioral changes manifest which would be
indicative for the retina as an early pre-clinical marker.
Furthermore, this would facilitate elucidation of whether the
changes seen in 5xFAD mice have developmental and/or
progressive components.
Assessment of inner retinal changes with OCT and ERG as
biomarkers for Alzheimer’s disease are favorable in terms of
their non-invasive and inexpensive nature. OCT in particular is
becoming increasingly widespread in optometric and ophthalmic
clinics. Utility of these retinal assays in the field of pre-clinical
and clinical assessment for developing new treatments for
Alzheimer’s remains to be seen, with further studies investigating
sensitivity/specificity assessment as well as cost/benefit analyses
required for future implementation.
CONCLUSION
To our knowledge, this is the first study to characterize
both retinal structure and function in 5xFAD mice over a
broad range of ages. We show that retinal neurodegeneration
associated with amyloid pathology follows a progressive
pattern similar to that of the brain. Amyloid pathology in
the eye leads to neurodegeneration of ganglion cell structure
(particularly their axons) and function, but interestingly a
slight thickening of the synaptic layer between bipolar cells,
amacrine cells, and ganglion cells. At the older ages, this
was accompanied by more widespread retinal dysfunction
encompassing the photoreceptors (a-wave), interneurons
(b-wave) and the inner retina (oscillatory potentials).
These data provide insight into specific patterns of early
retinal changes and disease progression associated with
amyloid pathology.
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